FDA Warning Letter to NexCell Scientific Inc (2026-09-11) — Unapproved New Drugs/Unlicensed Biological Product Violations
Letter issued · posted to fda.gov .
Subject as published: Unapproved New Drugs/Unlicensed Biological Product Violations
TL;DR
In short: The FDA's Center for Biologics Evaluation and Research (CBER) issued a warning letter to NexCell Scientific Inc (President Edwin Pinos) on September 11, 2026 (Reference CBER 26-730612) following inspections on December 9-12, 2025 and February 3-5, 2026, finding that the company manufactures an unapproved umbilical cord blood-derived total nucleated cell product for allogeneic use in violation of section 505(a) of the FD&C Act and section 351(a)(1) of the PHS Act. The letter cites website statements and a "White Paper study" characterizing the product's potential benefits for musculoskeletal, cardiovascular, neurological, and autoimmune conditions as evidence the product is intended for drug use without FDA approval or a biologics license. The letter also documents significant current good manufacturing practice (CGMP) violations under 21 CFR parts 210 and 211, rendering the product adulterated under section 501(a)(2)(B) of the FD&C Act, and states that introduction or delivery of the product into interstate commerce is prohibited.
Argus analysis
# FDA Warning Letter Analysis: NexCell Scientific Inc
**Company and Violations**
NexCell Scientific Inc, based in Irvine, California, received a warning letter from the FDA's Center for Biologics Evaluation and Research on September 11, 2026, following inspections in December 2025 and February 2026. The company manufactures umbilical cord blood-derived total nucleated cell products in multiple concentrations for allogeneic use. FDA documented that NexCell is distributing an unapproved new drug and unlicensed biological product without required regulatory authorization. The agency identified the violations through website statements and a company reference document claiming the product could treat inflammation, neurological conditions, liver cirrhosis, cardiovascular issues, and autoimmune diseases.
**Regulatory Citations and Meaning**
The violations center on two primary statutes: Section 505(a) of the Federal Food, Drug, and Cosmetic Act (requiring new drug approval) and Section 351(a)(1) of the Public Health Service Act (requiring biologics license approval). NexCell's product also fails to qualify for the limited 21 CFR Part 1271 exception for human cell/tissue products, which requires homologous use only—meaning the product must perform the same basic function in recipients as in donors. Since the product targets diseases umbilical cord blood doesn't naturally treat in donors, it requires full premarket approval. Additionally, FDA cited significant current good manufacturing practice violations under 21 CFR Parts 210 and 211, including failure to validate manufacturing processes, aseptic procedures, and laboratory controls.
**Timeline and Industry Monitoring**
The warning letter establishes that continued distribution is prohibited. Compliance officers in regenerative medicine should monitor NexCell's next steps: whether the company halts distribution, submits a biologics license application, or pursues alternative regulatory pathways. Similar cell therapy firms should review their own marketing claims and process validation documentation, as FDA's emphasis on claims-based drug determination signals increased scrutiny of website language and reference materials in this sector.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER NexCell Scientific Inc MARCS-CMS 730612 — September 11, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: Via UPS and EMAIL Reference #: CBER 26-730612 Product: Biologics Recipient: Recipient Name Edwin Pinos Recipient Title President NexCell Scientific Inc 2 Hughes Ste 200 Irvine , CA 92618-2055 United States ed@nexcellscientific.com Issuing Office: Center for Biologics Evaluation and Research United States WARNING LETTER September 11, 2026 CBER 26-730612 Dear Edwin Pinos: The United States Food and Drug Administration (FDA) inspected your facility, located at the above address, between December 9 and 12, 2025, and between February 3 and 5, 2026. During the inspection, FDA documented that your company manufactures an umbilical cord blood-derived total nucleated cell (TNC) product, in multiple concentrations, for allogeneic use (hereinafter, “your product”). This letter is to advise you that your product is an unapproved new drug in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Your product is also an unlicensed biological product in violation of section 351(a)(1) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(a)(1). A biological product for which a biologics license application (BLA) has been approved under section 351(a) of the PHS Act is not required to have an approved application under section 505 of the FD&C Act, 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act. Your introduction or delivery for introduction of your product into interstate commerce, or the causing thereof, is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. § 331(d). This warning letter also summarizes significant violations of current good manufacturing practice (CGMP) requirements, including violations of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. § 351(a)(2)(B), and 21 CFR parts 210 and 211 in the manufacture of your product. Because your methods, facilities, or controls for manufacturing, processing, packing, or holding drugs do not conform to CGMP, your product is adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. § 351(a)(2)(B). Your introduction or delivery for introduction of your product into interstate commerce, or the causing thereof, is a prohibited act under section 301(a) of the FD&C Act, 21 U.S.C. § 331(a). Unapproved New Drug and Unlicensed Biological Product Violations Based on information and records reviewed by FDA, your product is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and/or is intended to affect the structure or function of the body. For example: Your website www.nexcelllabs.com …
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
- What is the regulatory background for a Unapproved drug warning letter?
- Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has NexCell Scientific Inc had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for NexCell Scientific Inc as of 2026-09-22. Argus ingests new FDA enforcement records daily.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Warning Letter to NexCell Scientific Inc (2026-09-11) — Unapproved New Drugs/Unlicensed Biological Product Violations. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-nexcell-scientific-inc-2026-09-11-unapproved-drug
"FDA Warning Letter to NexCell Scientific Inc (2026-09-11) — Unapproved New Drugs/Unlicensed Biological Product Violations." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-nexcell-scientific-inc-2026-09-11-unapproved-drug.
Argus HQ Research. "FDA Warning Letter to NexCell Scientific Inc (2026-09-11) — Unapproved New Drugs/Unlicensed Biological Product Violations." Digital Empire Holdings LLC. Accessed September 23, 2026. https://argushq.ai/fda/warning-letter/fda-wl-nexcell-scientific-inc-2026-09-11-unapproved-drug.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_nexcell_scientific_inc_2026_09_11_unapproved_drug_2026,
title = {FDA Warning Letter to NexCell Scientific Inc (2026-09-11) — Unapproved New Drugs/Unlicensed Biological Product Violations},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-nexcell-scientific-inc-2026-09-11-unapproved-drug},
note = {Accessed: September 23, 2026}
}